- Parties: The applicants were Aragon Pharmaceuticals, Inc. and Janssen Inc. The respondent was Sandoz Canada Inc.

- Subject Matter: his is an action before the Federal Court under the Patented Medicines (Notice of Compliance) Regulations concerning Canadian Patent No. 2,885,415, relating to the apalutamide product ERLEADA and Sandoz’s proposed apalutamide product. The consolidated matters involve allegations that Sandoz’s product will infringe certain claims of the 415 Patent and Sandoz’s counterclaim that those asserted claims are invalid and that the patent was improperly listed on the Patent Register. The case is ongoing.

- Date: The hearing was set on May 19, 2026. 

- Venue: This was a federal case before the Federal Court. 

- Amount: No financial award was specified.